Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score

Fig. 2

The FRAX score among various prostate cancer therapies. a: The 10-year major osteoporotic risk. The EBRT and ADT monotherapy groups showed significantly higher FRAX scores than the brachytherapy group (p < 0.001, p < 0.001, respectively). b: The 10-year hip fracture risk. The EBRT and ADT monotherapy groups showed higher FRAX scores than both the brachytherapy group (p < 0.001, p < 0.001, respectively) and the prostatectomy group (p < 0.05, p < 0.001, respectively)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us